Posted by Michael Wonder on 08 Jul 2021
In a reversal, FDA calls for limits on who gets Alzheimer’s drug
8 July 2021 - The agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.
Facing sharp criticism for approving a controversial drug for all Alzheimer’s patients, the FDA on Thursday greatly narrowed its recommendation, suggesting that only those with mild memory or thinking problems should receive it.
